Summit Therapeutics Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. Unaudited results are reported in U.S. dollars. Summit is a development-stage biopharmaceutical company focused on novel antibiotics, including ridinilazole for C. difficile infection (CDI) and candidates from its Discuva Platform.
Financial performance and position
- Revenue: Q3 revenue was $1.3 million versus $0.2 million a year earlier; nine-month revenue was $1.6 million versus $0.7 million. Revenue came from the Eurofarma licensing agreement, including a $1.25 million enrollment milestone reached in September. Summit has not completed development of any drugs.
- Operating results: Q3 operating expenses were $25.6 million and other operating income was $4.8 million, resulting in an operating loss of $19.5 million. Net loss was $19.6 million, or $0.20 per share. For nine months, operating loss was $60.1 million and net loss was $61.5 million, or $0.68 per share.
- Research and development: Nine-month R&D expense rose 54.8% to $62.2 million, chiefly from Phase III ridinilazole activity and higher compensation and facilities costs. General and administrative expense decreased 2.2% to $15.8 million.
- Other operating income: Nine-month total was $16.4 million, comprising $11.7 million of U.K. R&D tax credits, $4.0 million of BARDA funding income, and $0.7 million of CARB-X grant income.
- Cash flow: Nine-month operating cash use was $63.4 million versus $40.1 million in 2020; investing cash use was $0.2 million. Financing provided $76.7 million, principally the net proceeds of the rights offering. Cash increased $13.8 million to $80.2 million.
- Liquidity and debt: At September 30, cash was $80.2 million, R&D tax-credit receivables were $21.4 million, and accounts receivable was $2.3 million. Total liabilities were $26.4 million; the related-party promissory note had been repaid after the May rights offering, and no borrowing balance is shown at period-end. Contractual operating lease obligations totaled $1.9 million.
- Margins: The filing does not present gross profit or gross margin, and product sales had not begun.
Material changes versus the prior comparable period
- Nine-month net loss increased to $61.5 million from $39.2 million, while operating cash use increased to $63.4 million from $40.1 million. R&D expense increased $22.0 million; other operating income rose $1.4 million, partly offsetting the higher spending.
- Summit raised $75.0 million gross through a fully subscribed May rights offering, issuing 14.3 million shares at $5.24 per share. Shares outstanding were 97.6 million at September 30, versus 82.6 million at December 31, 2020.
- The company combined its two blinded Phase III Ri-CoDIFy trials into one study. In September, FDA feedback rejected Summit’s proposed change to the primary endpoint.
- Stock-based compensation increased to $7.2 million for the nine months from $1.2 million a year earlier. A Q3 modification to performance-based options removed performance vesting criteria; 9.25 million options became granted under the modification.
Outlook, risks and contingencies
- Summit anticipated communicating combined ridinilazole top-line results in Q1 2022. The company said the results would inform next steps; any regulatory or commercial plans depend on the data and relevant approvals.
- Management expected current resources, before alternative cost reductions, to fund operations into Q3 2022. Including alternative operating plans that scale back spending, management estimated funding of operating costs and working capital into Q1 2023. These estimates depend on assumptions and may prove incorrect.
- Summit expects ongoing losses and says it will need additional capital. Potential financing includes equity, debt, or collaborations; availability and acceptable terms are not assured. Failure to secure funding could require reduced or discontinued programs.
- FDA disagreement with the endpoint change creates a material clinical and regulatory risk: FDA could also reject the trial combination, potentially impeding ridinilazole approval. The filing identifies COVID-19-related site disruptions, slower enrollment, and uncertainty as continuing risks.
- BARDA had committed $62.4 million, of which $55.8 million had been received by September 30, 2021; remaining potential funding depends on BARDA exercising its final option and milestone conditions. No material legal proceedings were reported.
Important facts for investors to verify
- Whether the combined Phase III trial design and endpoint will be acceptable to FDA, and the timing and interpretation of the top-line results.
- Whether management can secure additional financing if needed, and how actual spending and cash runway compare with its estimates.
- Progress and eligibility for remaining BARDA and CARB-X funding, R&D tax-credit receipts, and Eurofarma development milestones.
- The future expense and dilution implications of the substantial option grants and any further equity financing.